The nonclinical safety assessment aims at identifying potential toxicities associated with the administration of vaccines to humans, and does play a critical role in ensuring vaccine safety. At the upcoming World Vaccine Congress Asia 2013, Dr. Lawrence Segal will be speaking on the topic "Nonclinical safety assessment of vaccines, adjuvants, residuals and contaminants". He will be focusing on how to develop a regulatory framework for vaccine and adjuvant nonclinical safety assessments. He will also be evaluating vaccine and adjuvant toxicity to ensure safety for clinical testing and how to implement safety assessment of residuals, contaminants, extractables and leachables in vaccine products.
Dr. Lawrence Segal is currently the Director of Nonclinical Toxicology and Pharmacology in GlaxoSmithKline Vaccines, Belgium. Prior to joining GSK, he was employed as a senior toxicologist with GE Advanced Materials and Huntsman Europe and had worked for Health Canada in the fields of chemical, pesticide and pharmaceutical regulatory toxicology. Dr. Segal holds a PhD in Toxicology from the University of Saskatchewan and M.Sc. and B.Sc. in Biology from Carleton University.